Drugs / LYS006
Trials 4 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 2 | NCT04147195 | Jun 2020 → Jan 2022 | NAFLD1, metabolic dysfunction-associated steatohepatitis | Novartis Pharmaceuticals | Terminated | No outcome recorded |
| Phase 2 | NCT04074590 | Feb 2020 → Nov 2022 | ulcerative colitis | Novartis Pharmaceuticals | Terminated | No outcome recorded |
| Phase 2 | NCT03827798 | Feb 2019 → Dec 2024 overdue | hidradenitis suppurativa | Novartis Pharmaceuticals | Active not recruiting | No outcome recorded |
| Phase 2 | NCT03497897 | Sep 2018 → Feb 2022 | acne | Novartis Pharmaceuticals | Completed | No outcome recorded |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 5 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | LYS006 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT04074590 ↗ |
| Known as | CPD (S)-22 | ChEMBL registry synonym — accepted as the source's own label CHEMBL4852381 ↗ |
| Known as | LTA4H-IN-1 | ChEMBL registry synonym — accepted as the source's own label CHEMBL4852381 ↗ |
| Route | Oral | “LYS006 20 mg, capsules, oral administration” NCT03497897 ↗ |